RE: BOOM12 Dec 2025 07:58
The commercial interest in oral targeted therapies for multiple types of solid tumours, including prostate cancer, was recently demonstrated by the announcement on 17 November 2025 by Johnson & Johnson that it was acquiring Halda Therapeutics OpCo, Inc ("Halda") for US$3.05 billion in cash. Prior to the acquisition, Halda's Phase I/II clinical trial had demonstrated impressive preliminary efficacy and a strong early safety profile in prostate cancer.
Come on whats not to like sum big pharma going to come knocking at some point!